Amyloid β pathology in Alzheimer's disease and schizophrenia

American Journal of Psychiatry

Volumn 160, Issue 5, 2003, Pages 867-872

  Religa, Dorota ^a   Laudon, Hanna ^b   Styczynska, Maria ^b   Winblad, Bengt ^b   Näslund, Jan ^b   Haroutunian, Vahram ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA-PROTEIN (1-42); AMYLOID PRECURSOR PROTEIN; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ARTICLE; AUTOPSY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; SCHIZOPHRENIA; AGED; AMYLOIDOSIS; BRAIN DISEASE; BRAIN LEVEL; CHEMISTRY; COGNITIVE DEFECT; COMORBIDITY; COMPARATIVE STUDY; FEMALE; GERIATRIC ASSESSMENT; MALE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PREFRONTAL CORTEX; SENILE PLAQUE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOIDOSIS; BRAIN CHEMISTRY; BRAIN DISEASES; COGNITION DISORDERS; COMORBIDITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GERIATRIC ASSESSMENT; HUMANS; MALE; PEPTIDE FRAGMENTS; PREFRONTAL CORTEX; SCHIZOPHRENIA; SENILE PLAQUES;

EID: 0038182472     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.160.5.867     Document Type: Article

References (43)

1. Purohit DP, Perl DP, Haroutunian V, Powchik P, Davidson M, Davis KL: Alzheimer disease and related neurodegenerative diseases in elderly patients with schizophrenia: a postmortem neuropathologic study of 100 cases. Arch Gen Psychiatry 1998; 55:205-211
2. Buhrich N, Crow TJ, Johnstone EC, Owens DG: Age disorientation in chronic schizophrenia is not associated with pre-morbid intellectual impairment or past physical treatment. Br J Psychiatry 1988; 152:466-469
3. Johnstone EC, Owens DG, Gold A, Crow TJ, MacMillan JF: Institutionalization and the defects of schizophrenia. Br J Psychiatry 1981; 139:195-203
4. Taylor MA, Abrams R: Cognitive impairment in schizophrenia. Am J Psychiatry 1984; 141:196-201
5. Davidson M, Harvey PD, Powchik P, Parrella M, White L, Knobler HY, Losonczy MF, Keefe RSE, Katz S, Frecska E: Severity of symptoms in chronically institutionalized geriatric schizophrenic patients. Am J Psychiatry 1995; 152:197-207
6. Harvey PD, Davidson M, Powchik P, Parrella M, White L, Mohs RC: Assessment of dementia in elderly schizophrenics with structured rating scales. Schizophr Res 1992; 7:85-90
7. Arnold SE, Franz BR, Trojanowski JQ: Elderly patients with schizophrenia exhibit infrequent neurodegenerative lesions. Neurobiol Aging 1994; 15:299-303
8. Buhl L, Bojsen-Moller M: Frequency of Alzheimer's disease in a postmortem study of psychiatric patients. Dan Med Bull 1988; 35:288-290
9. Prohovnik I, Dwork AJ, Kaufman MA, Willson N: Alzheimer-type neuropathology in elderly schizophrenia patients. Schizophr Bull 1993; 19:805-816
10. Purohit DP, Davidson M, Perl DP, Powchik P, Haroutunian VH, Bierer LM, McCrystal J, Losonczy M, Davis KL: Severe cognitive impairment in elderly schizophrenic patients: a clinicopathological study. Biol Psychiatry 1993; 33:255-260
11. Powchik P, Davidson M, Haroutunian V, Gabriel SM, Purohit DP, Perl DP, Harvey PD, Davis KL: Postmortem studies in schizophrenia. Schizophr Bull 1998; 24:325-341
12. Dwork AJ, Susser ES, Keilp J, Waniek C, Liu D, Kaufman M, Zemishlany Z, Prohovnik I: Senile degeneration and cognitive impairment in chronic schizophrenia. Am J Psychiatry 1998; 155:1536-1543
13. Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotas A: Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry 1987; 48(May suppl):9-15
14. Rubin EH, Morris JC, Berg L: The progression of personality changes in senile dementia of the Alzheimer's type. J Am Geriatr Soc 1987; 35:721-725
15. Devanand DP, Jacobs DM, Tang MX, Del Castillo-Castaneda C, Sano M, Marder K, Bell K, Bylsma FW, Brandt J, Albert M, Stern Y: The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry 1997; 54:257-263
16. Stern Y, Tang MX, Albert MS, Brandt J, Jacobs DM, Bell K, Marder K, Sano M, Devanand D, Albert SM, Bylsma F, Tsai WY: Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA 1997; 277:806-812
17. Mortimer JA, Ebbitt B, Jun SP, Finch MD: Predictors of cognitive and functional progression in patients with probable Alzheimer's disease. Neurology 1992; 42:1689-1696
18. Mega MS, Cummings JL, Fiorello T, Gornbein J: The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996; 46:130-135
19. Jost BC, Grossberg GT: The evolution of psychiatric symptoms in Alzheimer's disease: a natural history study. J Am Geriatr Soc 1996; 44:1078-1081
20. Selkoe DJ: Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 1999; 399(6738 suppl):A23-A31
21. Jarrett JT, Lansbury PT Jr: Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 1993; 73:1055-1058
22. Hardy J: Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 1997; 20:154-159
23. Haroutunian V, Perl DP, Purohit DP, Marin D, Khan K, Lantz M, Davis KL, Mohs RC: Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease. Arch Neurol 1998; 55:1185-1191
24. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD: Correlation between elevated levels of amyloid p-peptide in the brain and cognitive decline. JAMA 2000; 283:1571-1577
25. Morris JC, Storandt M, McKeel DW Jr, Rubin EH, Price JL, Grant EA, Berg L: Cerebral amyloid deposition and diffuse plaques in "normal" aging: evidence for presymptomatic and very mild Alzheimer's disease. Neurology 1996; 46:707-719
26. Rajkowska G, Goldman-Rakic PS: Cytoarchitectonic definition of prefrontal areas in the normal human cortex, I: remapping of areas 9 and 46 using quantitative criteria. Cereb Cortex 1995; 5:307-322
27. Rajkowska G, Goldman-Rakic PS: Cytoarchitectonic definition of prefrontal areas in the normal human cortex, II: variability in locations of areas 9 and 46 and relationship to the Talairach coordinate system. Cereb Cortex 1995; 5:323-337
28. Dracheva S, Marras SAE, Elhakem SL, Kramer FR, Davis KL, Haroutunian V: N-Methyl-o-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia. Am J Psychiatry 2001; 158:1400-1410; correction, 158:2107
29. Morris JC: The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43:2412-2414
30. Harvey PD, Howanitz E, Parrella M, White L, Davidson M, Mohs RC, Hoblyn J, Davis KL: Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. Am J Psychiatry 1998; 155:1080-1086
31. Harvey PD, Parrella M, White L, Mohs RC, Davidson M, Davis KL: Convergence of cognitive and adaptive decline in late-life schizophrenia. Schizophr Res 1999; 35:77-84
32. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L: The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), part II: standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41:479-486
33. Khachaturian Z: Diagnosis of Alzheimer's disease. Arch Neurol 1985; 42:1097-1105
34. Wessel D, Flugge UI: A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal Biochem 1984; 138:141-143
35. Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, Kholodenko D, Malenka RC, Nicoll RA, Mucke L: Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci USA 1999; 96:3228-3233
36. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL: Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998; 95:6448-6453
37. Lee SJ, Liyanage U, Bickel PE, Xia W, Lansbury PT Jr, Kosik KS: A detergent-insoluble membrane compartment contains Aβ in vivo. Nat Med 1998; 4:730-734
38. Arnold SE, Trojanowski JQ, Gur RE, Blackwell P, Han LY, Choi C: Absence of neurodegeneration and neural injury in the cerebral cortex in a sample of elderly patients with schizophrenia. Arch Gen Psychiatry 1998; 55:225-232
39. Higaki J, Murphy GM Jr, Cordell B: Inhibition of beta-amyloid formation by haloperidol: a possible mechanism for reduced frequency of Alzheimer's disease pathology in schizophrenia. J Neurochem 1997; 68:333-336
40. DesJarlais RL, Seibel GL, Kuntz ID, Furth PS, Alvarez JC, Ortiz de Montellano PR, DeCamp DL, Babe LM, Craik CS: Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease. Proc Natl Acad Sci USA 1990; 87:6644-6648
41. Adler LE, Olincy A, Waldo M, Harris JG, Griffith J, Stevens K, Flach K, Nagamoto H, Bickford P, Leonard S, Freedman R: Schizophrenia, sensory gating, and nicotinic receptors. Schizophr Bull 1998; 24:189-202
42. Salomon AR, Marcinowski KJ, Friedland RP, Zagorski MG: Nicotine inhibits amyloid formation by the Aβ-peptide. Biochemistry 1996; 35:13568-13578
43. Seo J, Kim S, Kim H, Park CH, Jeong S, Lee J, Choi SH, Chang K, Rah J, Koo J, Kim E, Suh Y: Effects of nicotine on APP secretion and Aβ- or CT(105)-induced toxicity. Biol Psychiatry 2001; 49:240-247